LENVATINIB 10MG CAPSULE

LENVATINIB 10MG CAPSULE is a prescription oral targeted anticancer medicine used in the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), and renal cell carcinoma (RCC). It belongs to the class of multikinase inhibitors and is designed to target specific pathways involved in cancer growth and progression.

Lenvatinib works by inhibiting multiple tyrosine kinases that promote tumor angiogenesis (blood vessel formation) and cancer cell proliferation. Blocking these signaling pathways, it helps slow tumor growth, limit cancer spread, and support effective disease control in advanced cancers.

Administered orally, the Lenvatinib 10 mg Capsule offers the convenience of targeted cancer therapy for outpatient and long-term treatment plans. This product should be taken strictly under the supervision of a qualified oncologist, following prescribed dosage and monitoring guidelines to ensure safety and optimal treatment outcomes.

Product Features

• Oral targeted anticancer capsule
• Contains Lenvatinib 10 mg
• Multikinase inhibitor (VEGFR, FGFR, PDGFR)
• Used in thyroid, liver, and kidney cancers
• Once-daily oral dosing (as prescribed)
• High bioavailability oral formulation
• Manufactured under GMP-compliant standards
• Prescription-required oncology medicine

How It Helps

• Inhibits tumor blood vessel formation to restrict cancer growth
• Blocks multiple kinase pathways involved in cancer progression
• Slows tumor growth in thyroid, liver, and kidney cancers
• Provides effective targeted therapy under an oncologist’s supervision